Evidence map›Paper›PMID 33709324›Full record

ReviewCurrent HIV/AIDS reports2021

Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

Daniel C Rogan, Mark Connors

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Role of CXCR5Frontiers in microbiology · 2022
    Review
  5. Article
  6. Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel C RoganHIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9766-4166
Mark ConnorsHIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. mconnors@niaid.nih.gov.ORCID 0000-0002-2108-8705
National Institutes of Health · US

Funding

Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNPZIAAI000855 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CONNORS, MARK · 2009 to 2025
$20.0M
NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

purpose of reviewA large amount of data now exists on the virus-specific immune response associated with spontaneous or induced immunologic control of lentiviruses. This review focuses on how the current understanding of HIV-specific immunity might be leveraged into induction of immunologic control and what further research is needed to accomplish this goal. RECENT

findingsDuring chronic infection, the function most robustly associated with immunologic control of HIV-1 is CD8

Indexed as

HIV-1HIV InfectionsHIV SeropositivityAnimalsCD8-Positive T-LymphocytesHumansCD8+ T cellsHIV-1 controllersHIV-1 infectionImmune controlVaccinesVirus-specific immunity

Identifiers

PMID33709324
OpenAlexW3135130361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.